PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Detail   |   Print    Next page > 
     
Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder
2026-09-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
RIGHT CARE, RIGHT PLACE: NUHS MARKS A DECADE OF ADVANCING VALUE-BASED CARE, SAVING 18,225 BED DAYS
2026-09-15T    Health Care/Hospital   Medical/Pharmaceuticals 
Honda Prize 2026 Awarded to Professor Graeme M. Clark and Dr. Ingeborg Hochmair
2026-09-15T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
2026-09-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) Officially Opens
2026-09-15T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SleepRes Receives Frost & Sullivan's 2026 North America New Product Innovation Recognition for Excellence in Positive Airway Pressure Device Innovation
2026-09-14T    Computer/Electronics   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
NEXTBIOMEDICAL Marks Its Largest-Ever Presence at CIRSE 2026 with Exhibition Booth and Learning Center, Highlighting Global Clinical Evidence
2026-09-14T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
2026-09-14T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
2026-09-14T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
2026-09-14T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.